The Lancet | Sequential use of immune checkpoint inhibitors in renal cell carcinoma @TheLancetTV | Uploaded June 2023 | Updated October 2024, 4 hours ago.
Prof Sumanta Kumar Pal and Prof Toni K Choueiri present the findings of their trial, published in The Lancet in June 2023:

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, openlabel, phase 3 trial

Read the full paper: thelancet.com/journals/lancet/article/PIIS0140-6736(23)00922-4/fulltext?dgcid=youtube_video_lancet

Visit The Lancet at thelancet.com/journals/lancet/home?dgcid=youtube_video_lancet
Find out more at thelancet.com/?dgcid=youtube_video_lancet_lancet

* * *
Continue this conversation on social! Follow us today at…
Twitter.com/TheLancet
facebook.com/TheLancetMedicalJournal
LinkedIn.com/company/the-lancet